Date published: 2026-7-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

SUV420H2 CRISPR/Cas9 KO Plasmid (h): sc-404626

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • SUV420H2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SUV420H2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    SUV420H2 CRISPR/Cas9 KO Plasmid (h)

    sc-404626
    20 µg
    $397.00

    Overview

    KMT5C encodes the lysine methyltransferase SUV420H2, a chromatin-modifying enzyme that catalyzes trimethylation of histone H4 lysine 20 (H4K20me3). This mark is enriched in heterochromatin and supports higher-order chromatin compaction, replication timing control, and maintenance of genome stability through regulation of DNA repair pathway choice. SUV420H2 activity interfaces with epigenetic silencing programs and cell-cycle–linked chromatin remodeling, influencing transcriptional repression at repetitive elements and lineage-specific loci. Dysregulation of H4K20 methylation patterns and altered SUV420H2 expression have been associated with aberrant chromatin states observed in cancer and other genome-instability contexts, making KMT5C a useful node for epigenetics-focused mechanistic studies.

    SUV420H2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KMT5C gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KMT5C together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KMT5C open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SUV420H2 protein expression.

    This CRISPR knockout system enables efficient generation of KMT5C-deficient cell models for investigation of SUV420H2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting KMT5C exon(s) critical for SUV420H2 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple KMT5C genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by SUV420H2 CRISPR/Cas9 KO Plasmid (h) and SUV420H2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KMT5C locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by SUV420H2 HDR Plasmid (h) and SUV420H2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KMT5C homology arms to support homology-directed repair at defined KMT5C target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.